186413-79-6

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-2-methoxy-6-picoline is used as a reagent in the synthesis of aminopyridinecarboxylic acid and its derivatives. These synthesized compounds serve as precursors for the development of streptonigrin analogs, which are important in the pharmaceutical industry due to their potential therapeutic properties.

InChI:InChI=1/C7H10N2O/c1-5-3-4-6(8)7(9-5)10-2/h3-4H,8H2,1-2H3

Upstream product

• 19346-45-3 2-fluoro-3-nitro-6-methylpyridine 
• 112163-03-8 5-nitro-6-methoxy-2-methylpyridine 
• 186413-74-1 5-Bromo-6-methyl-3-nitro-1H-pyridin-2-one 
• 186413-75-2 3-bromo-6-chloro-2-methyl-5-nitropyridine 
• 68957-50-6 2-amino-5-bromo-6-methyl-3-nitropyridine 
• 186413-76-3 5-bromo-2-methoxy-6-methyl-3-nitropyridine 

Downstream Products

• 186413-98-9 N-(4-Iodo-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-2,2-dimethyl-propionamide 
• 186414-01-7 Trifluoro-methanesulfonic acid 4-(2-diethylcarbamoyloxy-3,4-dimethoxy-phenyl)-3-(2,2-dimethyl-propionylamino)-6-methyl-pyridin-2-yl ester 

Relevant academic research and scientific papers

COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES

The present invention concerns the compounds of formula (I) wherein R1, R2, R3, X, and Y are as described in the description, and their use as antagonists of the LPA1 receptor, in combination with one or more therapeutically active ingredients acting as anti-fibrotic agent(s); such as especially pirfenidone and/or nintedanib, in the prevention and/or treatment of fibrotic diseases. The invention further relates to pharmaceutical compositions comprising the compounds of formula (I) in combination with one or more therapeutically active ingredients acting as anti-fibrotic agent(s) such as pirfenidone or nintedanib.

ALKOXY-SUBSTITUTED PYRIDINYL DERIVATIVES AS LPA1 RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT OF FIBROSIS

The present invention relates to pyridinyl derivatives of Formula (I) Formula (I) wherein R1, R2, R3, R4, R5, R6, Ar1, L, W, Z, m and n are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as LPA1 receptor modulators.

Synthesis of new pyridine intermediates as precursors for the elaboration of streptonigrin analogues by the metalation-cross-coupling strategy

Starting from available 2-amino-6-chloro-3-nitropyridine, synthesis of 3-amino-6-pyridinecarboxylic acid derivatives precursor for pyridine ring C of streptonigrin analogues is described.